As a leading service provider in the field of antibody discovery and immunotherapy, Creative Biolabs now presents one-stop CAR-T therapy development service which has become a revolution in the area of cancer therapy. Now, We are proud to introduce mixed lymphocyte tumor reactivity assay (MLTR) as an efficient method to determine reactivity of engineered lymphocyte (CAR-T) and tumor cells to ensure CAR-T therapy.
The mixed lymphocyte tumor reactivity assay (MLTR), also known as mixed lymphocyte tumor cell assay (MLTuC), is a technology to measure the immunological reactivity between lymphocyte and tumor cell. This assay was first described by in 1970 and was based on the mixed lymphocyte response (MLR) method which is used to show the safety of implantable material. Creative Biolabs provides CAR-T one-stop service from basic research to clinical trials and beyond, and MLTR assay has been a critical technology in evaluating the effectiveness of different CAR-T cell products at preclinical stage.
Assay of Mixed Lymphocyte Tumor Reactivity
Mixed lymphocyte tumor reactivity assay is based on mixed lymphocyte reaction assay, and now it has been an effective means to assess the immunological response between lymphocytes and tumor cells in vitro. It starts with co-culture target tumor cells (including cell line or tumor cells derived from patients) with lymphocyte populations (engineered with tumor-specific chimeric antigen receptor or primary T cells derived from PBMC), and then assess the immunological tumor-killing capabilities including T cell viability, activation, proliferation, and cytotoxicity by flow cytometry, ELISA, ELISpot etc. This assay also supports the measurement of interested antagonist or antibodies through the blockade of immune checkpoints as per clients’ projects. Creative Biolabs offers this critical MLTR assay for our clients not only to validate the effectiveness of our CAR-T products, but also can help you to figure out a more promising approach to antitumor therapy.
Figure 1 Simple diagram of mixed lymphocyte tumor activity assay.
Highlight Features of Our Service
➢ Professional Ph.D. level scientists
➢ Skillful technologies and advanced platforms
➢ Time- and labor-saving
➢ Customized assay design
With years of extensive experience in the field of immunotherapy, Creative Biolabs has established advanced platforms to facilitate the projects of numerous worldwide customers. Our senior scientists promise timely troubleshooting to maximize the success of every project. We are dedicated to providing one-stop service to our clients from basic research to clinical trials. We offer the above assay but not limited to this. Please just let us know your requirement and our team will get back to you as soon as possible.
For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE